CuraGen is developing velafermin (CG-53135), human fibroblast growth factor-20 administered intravenously, for the potential treatment and prevention of oral mucositis (OM). By December 2004, phase II trials for the prevention of OM in cancer patients undergoing bone marrow transplant had been initiated, and in September 2005 CuraGen indicated that results from this study will be reported during the first quarter of 2006.